Composition of Concentrated Human Immunoglobulins
The invention proposes the use of a pharmaceutical composition comprising 200 g/L immunoglobulin G (IgG), between 200 and 250 mM glycine and between 15 and 25 ppm nonionic detergent particularly suitable for subcutaneous administration. In addition, the pH of the composition is between 4.6 and 5.0.
1 .- 14 . (canceled)
15 . A pharmaceutical composition, comprising:
200 g/L, ±5% immunoglobulin G (IgG),
between 200 and 250 mM glycine, and
between 15 and 25 ppm nonionic detergent,
wherein the composition has pH between 4.6 and 5.0.
16 . The pharmaceutical composition of claim 15 , wherein the IgG are human IgG.
17 . The pharmaceutical composition of claim 15 , wherein glycine is present at a concentration between 200 and 230 mM.
18 . The pharmaceutical composition of claim 17 , wherein glycine is present at a concentration of 215 mM, ±5%.
19 . The pharmaceutical composition of claim 15 , wherein the nonionic detergent is present at a concentration between 15 and 25 ppm.
20 . The pharmaceutical composition of claim 19 , wherein the nonionic detergent is present at a concentration of 20 ppm, ±10%.
21 . The pharmaceutical composition of claim 15 , wherein the nonionic detergent is selected from the group consisting of polysorbates and poloxamers.
22 . The pharmaceutical composition of claim 21 , wherein the nonionic detergent is polysorbate 20 or polysorbate 80.
23 . The pharmaceutical composition of claim 15 , wherein the nonionic detergent is Pluronic F68.
24 . The pharmaceutical composition of claim 15 , wherein the pH is 4.8±0.1.
25 . The pharmaceutical composition of claim 15 , wherein the composition is devoid of acetate salts and/or mannitol and/or albumin.
26 . The pharmaceutical composition of claim 15 , comprising:
200 g/L, ±5% IgG,
215 mM, ±5% glycine, and
20 ppm, ±10% nonionic detergent,
wherein the composition has pH 4.8±0.1.
27 . The pharmaceutical composition of claim 15 , wherein the composition is in liquid form.
28 . The pharmaceutical composition of claim 15 , wherein the composition has an osmolality between 300 and 400 mOsm/kg.
29 . The pharmaceutical composition of claim 28 , wherein the osmolality is about 240 mOsm/kg.
30 . The pharmaceutical composition of claim 15 , wherein the IgG is obtained by fractionation of blood plasma.